Celgene & the Multiple Sclerosis Association of America Bring MS MindShift Initiative & “Brain Bulb” Hot Air Balloon to F...
July 24 2019 - 7:30AM
Business Wire
Balloon Takes Flight at the 37th Annual
QuickChek New Jersey Festival of Ballooning to Elevate Importance
of Brain Preservation
Celgene Corporation (NASDAQ: CELG) and the Multiple Sclerosis
Association of America (MSAA) are bringing the MS MindShift: A New
View of MS initiative to the 37th Annual QuickChek New Jersey
Festival of Ballooning in Readington, NJ, on July 26-28, where the
MS MindShift “Brain Bulb” hot air balloon will fly to raise
awareness of multiple sclerosis (MS) and brain health.
MS MindShift is a national initiative that provides a new
perspective on MS and was launched in May ahead of World MS Day.
The campaign aims to educate about the critical role the brain
plays in the disease and what people living with MS can do to help
keep their brain as healthy as possible, for as long as
possible.
The MS MindShift Brain Bulb hot air balloon will be featured at
the Festival as a way to literally elevate the importance of having
a “brain first” perspective in MS. Just as keeping a balloon in
good condition keeps it soaring above the ground, shifting focus up
toward the brain today could change how people with MS live with
the disease tomorrow.
The QuickChek New Jersey Festival of Ballooning is the largest
summertime hot air balloon and music festival in North America. The
MS MindShift experience at this event will give attendees the
opportunity to learn more about the campaign first hand, see the
Brain Bulb balloon up close, and provide a chance to take a “lift
up” in the tethered hot air balloon while learning about a new
perspective on MS.
MS is a chronic and often debilitating disease that affects
nearly 1 million people in the U.S. In MS, the immune system
attacks the central nervous system -- which includes the spinal
cord and brain. Localized injury to the brain produces “lesions”
which disrupt the flow of information from the brain to the body
which may lead to symptoms and relapses.
“Damage from the inflammation caused by MS can lead to
inefficient communication in the brain. A process known as
neurological reserve allows the brain to tap into other areas not
affected by MS to communicate and perform tasks the affected area
no longer can,” said Krupa Pandey, M.D., multiple sclerosis
neurologist at Hackensack Meridian Health Hackensack University
Medical Center. “I encourage people living with MS to gain a better
understanding of the importance of brain health, including how
lifestyle changes may help maintain neurological reserve
longer.”
“We’re excited to partner with Celgene on the MS MindShift
campaign to raise awareness of this critical topic within the MS
community,” says Amanda Montague, Vice President of Education and
Healthcare Relations, MSAA. “This initiative aligns with our
mission to help improve the lives of people living with MS by
providing them with the knowledge and support needed to help manage
their condition.”
“Celgene is committed to providing education, resources and
tools that help support the MS community and those living with the
disease,” said Terrie Curran, President, Global Inflammation and
Immunology, Celgene. “Through the MS MindShift, we hope to bring
this new perspective on brain health directly to the community to
elevate this important conversation.”
People with MS and those who support them can learn more about
the campaign at MSMindShift.com, and join the online community on
Facebook for more information about the MS MindShift events.
About Celgene
Celgene Corporation, headquartered in Summit, New Jersey, is an
integrated global biopharmaceutical company engaged primarily in
the discovery, development and commercialization of innovative
therapies for the treatment of cancer and inflammatory diseases
through next-generation solutions in protein homeostasis,
immuno-oncology, epigenetics, immunology and neuro-inflammation.
For more information, please visit www.celgene.com. Follow Celgene
on Social Media: @Celgene, Pinterest, LinkedIn, Facebook and
YouTube.
Forward-Looking Statements
This press release contains forward-looking statements, which
are generally statements that are not historical facts.
Forward-looking statements can be identified by the words
"expects," "anticipates," "believes," "intends," "estimates,"
"plans," "will," "outlook" and similar expressions. Forward-looking
statements are based on management's current plans, estimates,
assumptions and projections, and speak only as of the date they are
made. We undertake no obligation to update any forward-looking
statement in light of new information or future events, except as
otherwise required by law. Forward-looking statements involve
inherent risks and uncertainties, most of which are difficult to
predict and are generally beyond our control. Actual results or
outcomes may differ materially from those implied by the
forward-looking statements as a result of the impact of a number of
factors, many of which are discussed in more detail in our Annual
Report on Form 10-K and our other reports filed with the U.S.
Securities and Exchange Commission, including factors related to
the proposed transaction between Bristol-Myers Squibb and Celgene,
such as, but not limited to, the risks that: management’s time and
attention is diverted on transaction related issues; disruption
from the transaction make it more difficult to maintain business,
contractual and operational relationships; legal proceedings are
instituted against Bristol-Myers Squibb, Celgene or the combined
company that could delay or prevent the proposed transaction; and
Bristol-Myers Squibb, Celgene or the combined company is unable to
retain key personnel.
Hyperlinks are provided as a convenience and for informational
purposes only. Celgene bears no responsibility for the security or
content of external websites.
All trademarks are the property of their respective owners.
© 2019 Celgene Corporation 07/19 US-CLG-19-0997
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190724005096/en/
Investors: Nina Goworek Executive Director, Investor Relations
908-673-9711 Media: Catherine Cantone Senior Director, Corporate
Communications 908-897-4256
Celgene (NASDAQ:CELG)
Historical Stock Chart
From Aug 2024 to Sep 2024
Celgene (NASDAQ:CELG)
Historical Stock Chart
From Sep 2023 to Sep 2024